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Background: Latent adenoviral infection may amplify cigarette smoke-induced lung inflamma-
tion and therefore play an important role in the development of chronic obstructive pulmonary
disease (COPD). Adenoviruses can evade the human immune response via their 19-kDa protein
(19 K) which delays the expression of class I human leukocyte antigen (HLA) proteins. The 19 K
protein shows higher affinity to HLA-B7 and A2 compared with HLA-A1 and A3. The receptor for
adenovirus (CXADR) and integrin b5 (ITGB5) are host factors which might affect adenovirus
infection. Therefore, we investigated the contribution of HLA, CXADR, and ITGB5 genetic vari-
ants to the presence of the E1A gene and to level of lung function.
Methods: Study subjects were assayed for HLA-B7, A1, A2 and A3 by PCR-based assays using
allele-specific primers. Polymorphisms of the CXADR and ITGB5 genes were genotyped by
PCR-based restriction fragment length polymorphism assays. Detection of adenoviral E1A gene
was performed by a real-time PCR TaqMan assay.
Results: E1A positive individuals had a lower FEV1 compared with E1A negative individuals.
However, there was no significant difference in E1A positivity rate between the high (HLA-B7
and A2) and low (HLA-A1 and A3) 19 K affinity groups. There was also no significant difference
in FEV1 level between each affinity group. There was no significant difference in E1A positivity
rate or lung function among the CXADR and ITGB5 genotypes.
Conclusions: Genetic variants in HLA, CXADR and ITGB5 do not influence latent adenoviral
infections and are not associated with COPD.
ª 2009 Elsevier Ltd. All rights reserved.4 806 9008; fax: þ1 604 806 8351.
c.ca (A.J. Sandford).
9 Elsevier Ltd. All rights reserved.
Polymorphisms and COPD 1673Introduction
Cigarette smoke-induced inflammation in the airways and
lung parenchyma plays an important role in the develop-
ment of chronic obstructive pulmonary disease (COPD).
Inflammation is the basis of the proteolytic destruction of
the parenchyma which causes loss of lung elastic recoil and
the pathologic lesion of emphysema as well as the remod-
eling process which narrows the bronchioles.1 These lesions
induce changes in lung function that include decreased
expiratory flow rate, increased airway resistance, hyper-
inflation and abnormal gas exchange. However, there is
considerable variability in the degree of airflow obstruction
induced by cigarette smoking,2 and only 10e15% of chronic
smokers develop COPD.3 These observations indicate that
additional risk factors must contribute to the development
of COPD.
Several studies have shown that childhood respiratory
illness is an important risk factor for COPD.4,5 Adenovirus
causes bronchiolitis, pneumonia and respiratory failure in
children,6e8 and persists as a latent infection in the
tonsils,9,10 peripheral blood lymphocytes11 and lung.12
Latency is due to integration of viral genes into human
genomic DNA.13 We have used animal experiments to
explore the possible consequences of latent adenoviral
infection and showed that latent adenovirus 5 infection
amplified the cigarette smoke-induced inflammatory
responses in the lung in a guinea pig model.14 We have
previously shown that adenoviral E1A protein can regulate
host gene expression by interacting with cellular tran-
scription factors and thus increase synthesis of inflamma-
tory mediators.15,16 For example, E1A regulates the ICAM-1
promoter through its proximal NF-kB binding site.17 We also
showed that COPD patients have more adenoviral E1A DNA
in their lung tissue than non-obstructed controls matched
for age, sex and smoking history12 and that expression of
this viral gene in lung epithelial cells18 is increased in those
with severe emphysema.19 Since this increase in the E1A
gene from the left end of the viral genome is found in the
absence of an excess of the E3 viral gene from the right
end,12 this suggests that the left-hand portion of the viral
DNA is integrated into the host genome. These findings
indicate that integrated adenoviral DNA, particularly the
E1A gene, could have several important consequences
relevant to the pathogenesis of COPD.
Adenovirus is able to evade the immune system to
establish long-term infection in the host. It is known that
adenoviral 19 K protein binds human leukocyte antigen
(HLA) class I molecules and retains them in the endoplasmic
reticulum, thus preventing their presentation of viral anti-
genic peptides at the cell surface20,21 and consequently
cytotoxic T cell recognition of adenovirus-infected cells is
averted.22 In a previous study, the affinity of the 19 K
protein for class I molecules was shown to depend on the
HLA allele involved.23 Specifically, HLA-A2.1 and B7 bind
very well to 19 K, whereas 6e30-fold less 19 K was associ-
ated with HLA-A1, A3 and Aw69.23 These data suggest the
possibility that individuals who have HLA-A2 and B7 alleles
may be less able to mount an immune response against
adenovirus infection than individuals with HLA-A1, A3 and
Aw69 alleles, and therefore may be more susceptible tolatent infection, amplification of lung inflammation and
hence decreased lung function. Therefore, the first aim of
this study was to investigate whether specific HLA types
were related to the presence of adenoviral E1A gene in the
lung and to decreased lung function among smokers.
If adenoviral infection is a co-factor in the development
of COPD then genetic variation in host susceptibility to
adenovirus infection and/or persistence could be a deter-
minant of disease. The human cellular receptor for Group B
Coxsackieviruses and type 2 and 5 adenoviruses (CXADR)24
may influence susceptibility to viral infection25 and poly-
morphisms in the CXADR gene could alter its affinity for the
virus or the level of the receptor on the cell surface.
Virus internalization into the target cells requires
subsequent interactions between the viral coat (or capsid)
proteins that form the penton base and cell surface integ-
rins avb3 and avb5.
26 These integrins, in particular avb5,
mediate adenovirus internalization into the cells.27 The
level of avb5 integrin was shown to predict the suscepti-
bility of cells in culture to adenovirus infection.28 There-
fore, polymorphisms that affect the level or amino acid
sequence of the av or b5 polypeptides may modulate
susceptibility to adenovirus infection. The av and b5 poly-
peptides are encoded by the integrin av (ITGAV) and b5
(ITGB5) genes, respectively. Therefore, the second aim of
this study was to determine whether specific poly-
morphisms of the CXADR and ITGB5 genes affect the pres-
ence of the E1A gene in the lungs of patients who have
COPD and their level of lung function.Material and methods
Subjects
The subjects for this study were recruited from patients
admitted to St. Paul’s Hospital to undergo lobar or lung
resection surgery for a localized lung cancer. All patients
gave informed consent and completed an interviewer-
administered questionnaire regarding smoking history,
occupational exposure to dust or fumes and respiratory
symptoms. All patients were Caucasians. Forced expiratory
volume in one second (FEV1), forced vital capacity (FVC)
and FEV1/FVC ratio were calculated. Patients in whom the
lung lesion was obstructing a segmental or larger bronchus
were excluded from the study as this may influence lung
function. Any patients who had functional or pathologic
evidence of a process other than those associated with
COPD and non-smokers were also excluded from this study.
DNA for genotyping was extracted from frozen lung
tissue or paraffin-embedded lung tissue using a standard
phenol/chloroform protocol or from blood using the
QIAamp DNA BloodMaxi kit (QIAGEN Inc. Mississauga,
Ontario).
For the analysis of HLA alleles, a total of 170 subjects, of
whom 93 (55%) were male and 77 were female (45%) with
a median age of 64 years (range, 25e84 years) were
included in the study. There were 89 DNA samples from
frozen lung tissue and 81 DNA samples from blood. Addi-
tional DNA samples were available to the investigators from
paraffin-embedded lung tissue but these could not be
Table 1 Genotyping results for each HLA group.
HLA group Total (n) Positive (%)/Negative (%) Allele frequencya Reported allele
frequency (Caucasians)b
HLA-B7 170 40 (24)/130 (76) 0.13 0.10e0.15
HLA-A2 170 73 (43)/97 (57) 0.24 0.20e0.28
HLA-A1 170 42 (25)/128 (75) 0.13 0.13e0.18
HLA-A3 170 46 (27)/124 (73) 0.15 0.11e0.15
a Allele frequencies were estimated assuming HardyeWeinberg equilibrium.
b From Imanishi et al.29
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type are shown in Table 1. The estimated allele frequencies
of each HLA group predicted by assuming HardyeWeinberg
equilibrium were similar to the reported Caucasian allele
frequencies.29
For the analysis of CXADR and ITGB5 polymorphisms,
a total of 312 subjects, of whom 198 (63.5%) were male and
114 were female (36.5%) with a median age of 63.4 years
(range, 25e84 years) were included in the study. We had 231
DNA samples from paraffin-embedded or frozen lung tissue
and 81 DNA samples from blood available. The genotype
frequencies of each polymorphism are shown in Table 2.
This study was approved by the University of British
Columbia/Providence Health Care Research Ethics Board.
All subjects provided written informed consent for the
study.
HLA-B7, A2, A2 and A3 genotyping
The subjects were genotyped by PCR assays using published
HLA group-specific primers.30,31 Of the five HLA types
previously tested for affinity to the 19 K protein,23HLA-Aw69
was excluded from this study because of its low allele
frequency in Caucasians. For the amplification of HLA-B7,
the sense and anti-sense primers were located in exon 3 of
the HLA-B gene and amplified a 119 bp PCR product. The
sense primer was 50-CAA GTG GGA GGC GGC CCG TGA-30 and
anti-sense primer was 50-TGG TAC CAG CGC GCT CCA GCT-30.
For the amplification of HLA-A2, the sense and anti-sense
primers were located in exon 3 of the HLA-A gene and
amplified a 136 bpPCRproduct. The sense primerwas 50-GGATable 2 Genotype frequencies of CXADR and ITGB5
polymorphisms.
Gene Polymorphism Genotype n (%)
CXADR Exon 7 AA 238 (81.5)
AG 49 (16.8)
GG 5 (1.7)
Intron 3 TT 123 (40.9)
TC 130 (43.2)
CC 48 (15.9)
ITGB5 Codon 473 CC 208 (70.7)
CT 72 (24.5)
TT 14 (4.8)
Codon 477 AA 278 (94.6)
AG 15 (5.1)
GG 1 (0.3)GCC CCG CTT CAT CGC A-30 and anti-sense primer was 50-CTC
CCCGTCCCAATACTCCGGA-30. For the amplification ofHLA-
A1 group of alleles, the sense and anti-sense primers were
designed by us to provide more specific amplification of
the HLA-A1 group. Primers were designed from exon 3 of the
HLA-A gene (http://www.ebi.ac.uk/imgt/hla/) which was
amplified as a 101 bp PCR product. The sense primer was
50-GCG GAC ATG GCA GCT CAG AT-30 and anti-sense primer
was 50-CGGAGCCCGTCCACGCACC-30. For the amplification
of the HLA-A3 group, the primers were located in exon 3 of
the HLA-A gene and amplified a 230 bp product. The sense
primer was 50-GGT TCT CAC ACC ATC CAG ATA-30 and anti-
sense primerwas 50-CCA CTC CACGCACGTGCC A-30. In order
to verify that all samples contained amplifiable DNA, internal
control primers that amplified a 394 bp fragment of the
CXADR gene (exon 2)32 were added in each reaction mixture.
The control sense primer was 50-CTG GGC ATC TCT TGA GTT
TGGA-30, and theanti-senseprimerwas 50-ACTGGCAAGGTG
ATG GAC ACA T-30.
Optimized PCR conditions for HLA-B7 typing were as
follows: the PCR reaction mixture in a final volume of 20 ml
consisted of 100 ng genomic DNA, 1.5 mM MgCl2, 200 mM
each of dATP, dCTP, dGTP and dTTP, 0.4 mM of each HLA-B7
primer and 0.5 mM of each control primer, and 0.5 U DNA
Taq Polymerase (Hotstar Taq, Qiagen Inc, Mississauga,
Ontario). PCR conditions for cycling were optimized using
the touch down method33 as follows: initial denaturation
step at 95 C for 15 min, followed by 5 cycles of 94 C for
30 s, 68 C for 30 s, and 72 C for 45 s, followed by 10 cycles
with a decreased annealing temperature of 67 C, 20 cycles
at 66 C and a final extension for 10 min at 72 C. Optimized
PCR conditions for HLA-A2 typing were the same as for HLA-
B7 except that 0.15 mM HLA-A2 primers were used. Opti-
mized PCR conditions for HLA-A1 typing were the same as
for HLA-B7 except that 0.1 mM of each HLA-A1 primer and
1.0 mM of each control primer were used and 5 cycles of
94 C for 30 s, 70 C for 30 s, and 72 C for 45 s, followed by
10 cycles with a decreased annealing temperature at 69 C,
20 cycles at 68 C replaced the respective steps of the HLA-
B7 PCR. Similarly, optimized PCR conditions for HLA-A3
typing were the same as for HLA-B7 except that 0.5 mM of
each HLA-A3 primer and 0.1 mM of each control primer were
used and after the denaturation step PCR followed with 35
cycles of 94 C for 30 s, 62 C for 30 s, and 72 C for 45 s and
a final extension for 10 min at 72 C. All PCR amplification
were performed in a PCR EXPRESS Thermal Cycler (Thermo
Hybrid, Ashford, Middlesex, UK), and PCR products were
loaded on 2% agarose gels stained with ethidium bromide
and visualized in ultra-violet illumination.
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Putative polymorphisms of CXADR on chromosome 21q11.2
were identified in the NCBI database and five single
nucleotide polymorphisms (SNPs) were present in the
coding region. Genotyping of these putative SNPs revealed
that only one (a synonymous SNP in codon 282) was poly-
morphic in 30e50 DNA samples. The subjects were geno-
typed by PCR-based restriction fragment length
polymorphism assays. The primers for the exon 7 poly-
morphism in codon 282 (rs437470) were designed from the
CXADR gene sequence (GenBank accession # AF242865).
The sense primer was 50-CAG GCT CTT ATC CAT GAT TC-30
and the anti-sense primer was 50-AAT CAT CAC AGG AAT
CGC AC-30. The primers produced an amplified product of
321 bp. PCR was carried out in a 10 ml volume reaction
mixture containing 100 ng of genomic DNA, 0.5 units of Taq
DNA polymerase (Hotstar Taq, Qiagen Inc.), 1.5 mM (for
blood and frozen lung tissue DNA) or 3.0 mM (for paraffin
tissue DNA) MgCl2, 0.5 mM of each primer and 200 mM dNTPs.
Amplification conditions were as follows: an initial dena-
turation step at 95 C for 15 min, 30 cycles (for blood and
frozen tissue DNA) or 40 cycles (for paraffin tissue DNA) of
94 C for 30 s, 55 C for 30 s, 72 C for 45 s, followed by one
incubation at 72 C for 10 min. Restriction enzyme diges-
tions were performed in a total volume of 20 ml with 10
units of AciI (New England Biolabs, Mississauga, Ontario) at
37 C overnight. This enzyme produced digestion products
of 219 and 102 bp if the G allele was present and left an
uncut product of 321 bp in the case of the A allele.
We also chose one intronic SNP (rs764657) for genotyp-
ing; the selection being based on the ability to use a RFLP
assay for the SNP and a high minor allele frequency. The
primers for this intron 3 CXADR polymorphism were
designed from the GenBank sequence AF242864. The sense
primer was 50-CAT GAT GTG GCT CAG TTC AC-30 and anti-
sense primer was 50-TCT CTT CGG CAA TCA CTT CC-30. The
primers produced an amplified product of 249 bp. PCR was
carried out in a 20 ml volume reaction mixture containing
same reagents as described above. Amplification conditions
were also the same as before except that 40 cycles were
used for all samples. Restriction enzyme digestions were
performed in a total volume of 10 ml containing 10 units of
AluI (New England Biolabs) at 37 C for overnight. This
enzyme produced cut bands of 217 and 32 bp if the T allele
was present and an uncut band of 249 bp if the C allele was
present. All digested PCR products were loaded on 2%
agarose gels stained with ethidium bromide and visualized
with ultra-violet illumination.ITGB5 genotyping
Putative polymorphisms of the ITGB5 gene on chromosome
3q21 were also found in the NCBI database and six SNPs
were in the coding region. We performed direct
sequencing for all six potential SNPs using 10 DNA samples
and three were shown to be polymorphic. We found one
potentially functional SNP which causes a substitution of
amino acid 477 from asparagine to serine (rs2291087). The
other two SNPs were silent mutations, and of these, we
chose one SNP (rs2291088) located in codon 473 forgenotyping. The primers for the 473 polymorphism were
designed from the ITGB5 gene sequence (GenBank acces-
sion# NM_002213). The sense primer was 50-AGC AGA CAC
ACG GAG CAT GT-30 and the anti-sense primer was 50-CCT
GGC ACA GGA GAA GTT GT-30. The primers produced an
amplified product of 369 bp. PCR was carried out as
described for the CXADR intron 3 polymorphism except
that the annealing steps were performed at 57 C.
Restriction enzyme digestions were performed in a total
volume of 10 ml containing 10 units of HhaI (New England
Biolabs) at 37 C overnight. This enzyme produced cut
bands of 251 and 118 bp if the C allele was present and an
uncut band of 369 bp for the T allele.
The sense primer for the 477 polymorphism was the same
as that for the 473 polymorphism and the anti-sense primer
was 50-TCT GGT ACA CGC TCT GGT TC-30. The primers
produced an amplified product of 229 bp. PCR was carried
out as described for the 473 polymorphism. Restriction
enzyme digestions were performed in a total volume of 10 ml
containing 10 units of MspA1I (New England Biolabs) at 37 C
for overnight. This enzyme produced cut bands of 128 and
101 bp if theGallelewas present and anuncut band of 229 bp
from the A allele. Digested PCR products were loaded on 2%
agarose gels stained with ethidium bromide and visualized
with ultra-violet illumination.Detection of the adenoviral E1A gene
Real-time PCR detecting a portion of the E1A coding region
was performed using a TaqMan assay. The primers were
designed from the sequence of the type 5 adenoviral E1A
gene (GenBankAcc. No. AY147066). The sense and anti-sense
primer sequences were 50-GGA GGT GAT CGA TCT TAC CT-30
and50-CCGTATTCCTCCGGTGATAA-30withanamplifiedPCR
product size of 143 bp. A TaqMan probe was designed using
the Primer Express software (Applied Biosystems, Foster
City, CA). The sequence of TaqMan probe was 50-CTG GCT
TTC CAC CCA-30, with 6-carboxyfluorescein (6-FAM) fluores-
cent dye on the 50 end and a non-fluorescent quencher, and
a minor groove binder on the 30 end. PCR was carried out in
a 10 ml volume using a 384-well plate containing 0.5 mM of
each primer, 100 nM of TaqMan probe, 5 ml of 2X TaqMan
Universal Mastermix (Applied Biosystems) containing uracil-
DNA glycosylase, and 50 ng of each DNA sample. A blank (no
DNA template included) was added in each reaction. Serial
ten-fold diluted (101e105 copies/ml) type 2 adenovirus DNA
(GIBCO BRL, Burlington, Ontario) was used for making
a standard curve. The PCR reactions were performed in an
ABI PRISM 7900 HT Sequence Detection System (Applied
Biosystems). After uracil-DNAglycosylase digestion (50 C for
2 min) and enzyme activation (95 C for 10 min), 48 two-step
cycles were performed; 15 s denaturation at 95 C followed
by 1 minute annealing and extension at 60 C. After PCR, the
fluorescence of 6-FAM was measured in each well using the
ABI PRISM 7900 HTsystem. The quantification was repeated
in order to obtain four data points for each sample.
Normalization of the amount of DNA template was achieved
by amplification of the beta-actin gene and standard curves
for this assay were made by the serial dilution of human
genomic DNA (Applied Biosystems). The final copy numbers
of the E1A gene were adjusted according to these data.
Table 3 E1A positivity in replicate real-time PCRs.
Number of replicate
samples with E1A positive PCR
Number of individuals Mean (SD) number of copies of E1A




2/5 8 4.5 (6.6)
1/5 6 0.5 (0.4)
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The results are presented for each HLA (HLA-B7, A2, A1,
and A3) group; i.e. individuals either heterozygous or
homozygous for each HLA allele. Differences in positivity
for E1A were assessed by Fisher’s exact test between the
19 K high affinity (HLA-A2 and B7) and low affinity (HLA-A1
and A3) groups. Differences of E1A positivity rate between
CXADR and ITGB5 genotypes were assessed by c2 or Fisher’s
exact tests as appropriate. Associations were also analyzed
by logistic regression to adjust for potential confounding
factors, i.e. age, sex, and smoking history (pack years).
Linkage disequilibrium estimation was done using the
Arlequin software package.34 Differences in FEV1 level were
assessed by unpaired t tests. All tests were performed using
the JMP Statistics software package (SAS Institute Inc.). All
continuous variables were expressed as mean SEM.
Results
Detection of the adenovirus E1A gene
by TaqMan PCR assays
The 231 DNA samples derived from paraffin-embedded or
frozen lung tissue were analyzed for the presence or
absence of the E1A gene by TaqMan real-time PCR. In total,
19 samples (8.2%) showed a positive PCR for the E1A gene in
at least one of the five reactions whereas the remaining 212
samples (91.8%) were not positive in any reaction. A
summary of the E1A positive samples is shown in Table 3.
Comparison of FEV1 level between E1A positive
and negative groups
Individuals who showed at least one positive E1A PCR were
classified into an E1A positive group (nZ 19) and their
mean FEV1 level was compared with the E1A negative group
(nZ 212). The mean FEV1 level of the E1A positive
group was significantly lower than the E1A negative group
(62.2 4.8 vs. 72.5 1.4; p< 0.04). The p-value after
adjustment for age, sex, and smoking history (pack years)
still showed a borderline value (pZ 0.06).Table 4 Comparison of FEV1 levels among each HLA group.
HLA-B7 (þ), nZ 40 HLA-A2 (þ), nZ
FEV1 level 82.5 3.1 78.7 2.3
Values are expressed as mean SEM percent predicted. There wereWe also investigated whether COPD patients had
a higher positive rate of E1A compared with patients who
had normal lung function. Individuals who had an
FEV1< 80% predicted and FEV1/FVC< 70% were classified
as having COPD (nZ 151) and those with an FEV1> 85%
predicted and FEV1/FVC> 75% were classified as non-
obstructed (nZ 57). Using these criteria 23 out of 231
individuals with intermediate levels of lung function were
excluded. The COPD group had a higher E1A positive rate of
10.6% (16/135) compared with the controls with 3.5% (2/
55), but this difference was not statistically significant
(adjusted pZ 0.18).
Comparison of E1A gene positivity among
the HLA groups
Contrary to our hypothesis, the HLA-A1 or A3 (low 19 K
affinity) positive groups had a higher positive rate for E1A
(20.0% and 4.6%, respectively) compared with B7 or A2
(high 19 K affinity) positive groups (0%, 2.5%, respectively).
However, none of the differences between the groups were
statistically significant. A subset of the study subjects had
two (e.g. A2 and A3) or three (e.g. B7, A2 and A1) of the
HLA types that had previously been investigated for affinity
for 19 K. Therefore, we excluded these samples and
compared the E1A positivity rate between each affinity
group. Although the high 19 K affinity (A2 or B7 positive
without A1 or A3) group had a lower E1A positive rate (2.9%)
compared with the low affinity group (A1 or A3 positive
without A2 or B7) (18.2%), there was no significant differ-
ence between the groups (pZ 0.08).
Comparison of FEV1 level among the HLA groups
FEV1 values for HLA type are presented in Table 4. Since
this table includes the individuals who were double or triple
positive for the HLA types of interest, we also compared
the FEV1 level between each affinity group as described
above (Table 5). There was no significant difference in FEV1
value between the high 19 K affinity group (A2 or B7 posi-
tive without A1 or A3 positive) and low affinity group (A1 or
A3 positive without A2 or B7 positive) (pZ 0.78).73 HLA-A1 (þ), nZ 42 HLA-A3 (þ), nZ 46
75.9 3.0 82.8 2.9
no significant differences between the groups.
Table 5 Comparison of FEV1 levels between the 19 K high affinity (B7 or A2) and low affinity (A1 or A3) HLA groups.
HLA-B7 or A2, nZ 56 HLA-A1 or A3, nZ 45 p-value
FEV1% predicted 77.4 2.3 76.5 2.6 0.78
Values are expressed as mean SEM percent predicted.
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and genotyping
Direct sequencing of the CXADR exonic and promoter
regions in 10 DNA samples did not reveal additional poly-
morphisms to those in the NCBI database. There was strong
but not complete linkage disequilibrium between the two
CXADR polymorphisms (D0Z 0.97, r2Z 0.20, p< 0.0001).
There was no significant linkage disequilibrium between the
two ITGB5 polymorphisms even though they are only 11 bp
apart (D0Z 0.32, r2Z 0.001, pZ 0.53).
Comparison of E1A positivity rate among CXADR
and ITGB5 genotypic groups
Positivity for the E1A gene in groups of subjects divided by
the different SNP genotypes is presented in Table 6. For the
statistical analysis, individuals who were heterozygous and
homozygous for the minor allele were combined into the
same group since there were too few individuals to analyze
each group separately. However, there were no significant
differences in E1A positivity between any genotypic groups.
We also performed two-point haplotype analysis for both
genes but no significant association with E1A positivity was
found (data not shown).
Comparison of FEV1 level among CXADR and ITGB5
genotypic groups
The mean FEV1 was also compared in each CXADR and
ITGB5 genotypic group. However, we found no significant
difference in FEV1 between any genotypic group (data not
shown). We also performed two-point haplotype analysis
for both genes but no significant association was found
(data not shown).Table 6 E1A positivity in different genotypic groups.
Gene Polymorphism Genotype E1A p
CXADR Exon 7 AA 16 (9.
AG 2 (5.
GG 0 (0.
Intron 3 TT 7 (8.
TC 7 (7.
CC 4 (10
ITGB5 Codon 473 CC 15 (9.
CT 2 (3.
TT 0 (0.
Codon 477 AA 17 (8.
AG 1 (8.
GG 0 (0.
a Adjusted for age, sex, and smoking history (pack years) and groupDiscussion
We have previously shown that latent adenovirus 5 infec-
tion amplifies cigarette smoke-induced inflammatory
responses in the lung in a guinea pig model.14 We found that
adenoviral E1A gene which integrates into human DNA13 is
expressed in human lung cells.18 This viral protein can
interact with cellular transcription factors and thus regu-
late host gene expression of inflammatory mediators such
as interleukin-8 and intracellular adhesion molecule-1.15,16
In addition, we previously found that COPD patients have
higher copy number of the adenoviral E1A gene in their lung
compared with non-obstructed controls matched for age,
sex, and smoking history.12 These findings suggest that
latent adenovirus infection, and specifically the E1A gene,
amplifies the chronic inflammatory response that contrib-
utes to the development of COPD in smokers.
One purpose of the current study was to investigate
whether the presence of adenoviral E1A gene was related
to FEV1% predicted among smokers. In this study, we used
a real-time PCR method employing a TaqMan probe to
detect the E1A gene. In total, we could detect the E1A
gene in 19 DNA samples (8.2%) and found that these indi-
viduals had a lower FEV1 percent predicted (62.2 4.8)
than the E1A negative group (72.5 1.4). Our real-time
PCR result suggests that the presence of adenoviral E1A
gene in human lung DNA results in lower FEV1 in smokers
and supports findings of our previous semi-quantitative
analysis.12 These current results are also in keeping
with the report of increased adenoviral E1A expression in
severe emphysema.19
Viruses such as adenovirus have mechanisms for evading
the immune response to establish long-term infection in the
host. These strategies for immune evasion include inhibi-
tion of various steps in the class I MHC assembly pathway.
HLA molecules bind foreign antigens and present them to Tositive, N (%) E1A negative, N (%) p-valuea
2) 158 (90.8) 0.45
9) 32 (94.1)
0) 3 (100)
0) 81 (92.0) 0.90
5) 87 (92.5)
.5) 34 (89.5)
9) 136 (90.1) 0.10
9) 50 (96.1)
0) 10 (100)
5) 183 (91.5) 0.91
3) 11 (91.7)
0) 1 (100)
ing rare homozygotes with heterozygotes.
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or helper T cells by recognition of the antigen-HLA
complex. This mechanism is central to the elimination of
virus infected cells. However, in the case of adenovirus, the
19 K protein is retained in the endoplasmic reticulum via its
short cytoplasmic tail35,36 and its luminal domain binds
specifically to heavy chains of HLA.37 As a result, the
intracellular transport, terminal glycosylation, and cell
surface expression of class I MHC is dramatically inhibited.
The intracellular transportation of class I MHC in the
endoplasmic reticulum also requires the co-operative
function of several co-factors such as transporter associ-
ated with antigen processing (TAP).38 The 19 K protein also
binds TAP and acts as a TAP inhibitor preventing class I MHC
and TAP association.39 Interestingly, the results of
a previous study showed that the strength of interaction
between 19 K and different HLA types may influence the
susceptibility of individuals to persistent infections.23 HLA-
A2 and B7 bound with high affinity to 19 K, whereas HLA-A1
and A3 were associated with 6e30-fold less 19 K.23 There-
fore, we hypothesized that individuals who have HLA-B7
and A2 would have more integrated adenoviral DNA than
HLA-A1 and A3 positive individuals. This integrated DNA
could result in increased E1A synthesis and therefore
increased airway inflammation.
Based on these data, we investigated whether specific
HLA types affect the level of integrated adenoviral E1A gene
and also affect the level of FEV1. We did not find any asso-
ciation between specific HLA types and the E1A positivity
rate, or the level of FEV1 andourfindings suggest that theHLA
types we studied are not related to latent adenoviral infec-
tion and subsequent airway obstruction. With any negative
study it is important to calculate the power of the experi-
mental design to detect a difference. Therefore, we per-
formed a post-hoc power analysis of our study design. Given
the numbers in this study we should have been able to detect
a relative risk of 6.8 for HLA-A2/B7 as a risk factor for E1A
positivity and a difference in mean FEV1 9.8% predicted
between the HLA-A2/B7 and HLA-A1/A3 groups (given
aZ 0.05 and bZ 0.80 for two sided tests). Therefore, the
majorweakness of this study is the possibility that the lack of
association was due to type 2 error.
Products of HLA-A/B alleles that are bound by the 19 K
protein are thought to allow immune evasion. However, is it
also possible that by promoting immune evasion, viral
replication will be allowed to proceed so that the infected
host cell is ultimately killed and this may result in
decreasing E1A gene retention by that cell.
HLA molecules play key roles in the immune response and
have been identified as susceptibility or resistance genes for
a number of diseases. There have been few studies which
have investigated the potential association betweenHLA and
COPD. Kauffmann and colleagues demonstrated a significant
increase of HLA-B7 in non-smokers who had low FEV1 levels
comparedwith heavy smokerswho had high FEV1 levels (odds
ratio 3.8, p-valueZ 0.05).40 This result suggests thatHLA-B7
might be one of the risk factors for COPD. Maranetra and
colleagues reported a significant increase in HLA-Bw60
frequency in a group of COPD patients with low ventilatory
drive (odds ratio 42, p-valueZ 0.03).41 This finding suggests
that HLA-Bw60 might be related to ventilatory response to
CO2 in COPD.HLA typing was performed in a Japanese patient group
who had diffuse panbronchiolitis (DPB) which is a distinc-
tive form of COPD of unknown etiology.42,43 The results
demonstrated strong association between HLA-Bw54 and
DPB (relative riskZ 13.3 and ORZ 3.4 compared with the
control group). Although these specific HLA types have
been shown to be candidates for COPD and related
phenotypes, the biological mechanism(s) by which HLA
variants could contribute to susceptibility has not been
sufficiently studied.
We also hypothesized that polymorphisms in specific
human genes could influence susceptibility to latent
adenovirus infection. We investigated two candidate genes
which might affect latent adenoviral infection and the
subsequent development of COPD. Adenovirus infection
is initiated by attachment of the viral fiber knob to
CXADR, a 46-kDa integral membrane glycoprotein24 that is
expressed in a wide range of human and murine cell
types.44 The gene that encodes CXADR consists of seven
exons that are distributed over an area of 54 kb and
produces a 365 amino acid protein.32 The integrins, a family
of heterodimeric transmembrane glycoproteins, are the
major cell surface receptors responsible for cell adhesion
to matrix.45,46 The adenoviral coat protein, penton base,
binds to cell surface integrins avb3 and avb5. In this study,
we genotyped two SNPs in CXADR and two in ITGB5. We did
not find any obviously functional SNPs in the CXADR gene
although in the ITGB5 gene we found one amino acid
changing SNP. There were no associations of any of the SNPs
with E1A positivity or FEV1 level. In this study, we did not
analyze the ITGAV gene polymorphisms which might also
affect the viral internalization into the cells. Further study
is needed to clarify the correlation between SNPs of this
gene and E1A positivity.
In summary, our data show that E1A positive individuals
have a lower FEV1 compared with E1A negative individuals.
This result supports the suggestion that the presence of the
E1A gene in lung tissue DNA affects lung function in
smokers. We investigated the contribution of specific HLA
types to adenoviral mediated COPD. Our finding of a lack of
association indicates that HLA-B7, A1, A2, and A3 types do
not substantially influence latent adenoviral infections and
are not associated with COPD. In addition, polymorphisms
of the CXADR and ITGB5 genes did not affect the presence
of adenoviral E1A gene.
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